Loading company…
Molecular Partners develops DARPin-based therapies, including treatments for cancer.
Founded in 2004, Molecular Partners develops DARPin therapeutics, including multispecific T cell engagers targeting cancer antigens and a program targeting DLL3. Its work focuses on oncology and serves healthcare providers, specialists and research institutions. The company is based in Zurich, Switzerland. On June 16, 2021, it raised USD 63.75 mn in a private placement and follow-on round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in